Moho Resources Ltd (ASX:MOH) has identified high nickel sulphide potential after receiving results from exploration at the Silver Swan North project in Western Australia. The potential has been revealed by surveys, mapping. a reassessment of soil geochemistry and studying results from an historical drill hole. Historical hole This hole intersected 5 metres of sediment from 255 metres containing 10-40% sulphides, or up to 0.1% nickel before ending in ultramafic rocks. A downhole EM survey at the time detected a large, late time off-hole response towards the bottom and south of the drill-hole but this was not followed up. Survey identifies conductors Moho’s high sensitivity low temperature SQUID EM survey has identified three new conductors near this hole, which represent drill targets. Reassessment of soil geochemistry by Moho’s consultant Richard Carver has also highlighted several areas of nickel anomalism. A detailed ground gravity survey completed last quarters has highlighted an untested gravity high associated with the untested historical EM anomaly. Noisy nickel neighbours These results have proved encouraging for the company as ultramafic rocks within the Black Swan Komatiite Complex (BSKC) host a number nickel sulphide mines. These include the Silver Swan, Black Swan and Cygnet nickel sulphide deposits as well as Poseidon Nickel Ltd’s Black Swan nickel processing and concentrator facility. Drilling is planned Moho plans to drill up to five reverse circulation holes to test the new EM conductors in late February, subject to approval from the Department of Mines Industry and Safety. The SQUID EM survey has been extended over anomalous Target Zone 4 and to the boundary with Poseidon’s mining lease with a further extension planned over other areas. Moho will also undertake a major geochemical and straitigraphic aircore drill program across the northern area to identify suitable host rocks for nickel sulphide mineralisation under cover. - Jessica Cummins
Reported by Proactive Investors 3 hours ago.
Moho Resources identifies high nickel sulphide potential at Silver Swan North in WA
↧
↧
BB Biotech invests gains of M&A transactions in new technologies - dividend of CHF 3.05 proposed (news with additional features)
DGAP-News: BB BIOTECH AG / Key word(s): Quarterly / Interim Statement
18.01.2019 / 07:00
The issuer is solely responsible for the content of this announcement.
--------------------
Media release as of January 18, 2019
Portfolio of BB Biotech AG as of December 31, 2018
*BB Biotech invests gains of M&A transactions in new technologies - dividend of CHF 3.05 proposed**BB Biotech performed well last year in a the challenging stock market environment. Although its total return was a negative -5.2% in CHF (-2.2% in EUR), this was much better than the portfolio performance of -14.5% in CHF and -11.1% in EUR, which reflects the high level of confidence shareholders have in BB Biotech. During the course of the year BB Biotech realized significant gains on the disposal of three portfolio positions but those gains were unable to completely offset the negative returns from existing major portfolio shareholdings and the generally weak stock market performance. Severe market corrections in December more than erased the gains that BB Biotech had been making over the preceding eleven months. Its shares ended the fourth quarter down -18.8% in CHF and -17.2% in EUR, while its portfolio shed -18.2% of its value in CHF and -17.3% in EUR. BB Biotech incurred a net loss of CHF 643 mn for the fourth quarter and CHF 471 mn for the year as a whole. Management will continue the process of realigning the portfolio to capture future growth trends in the biotech sector. In spite of the unfavorable conditions on financial markets, the biotech sector is making tremendous strides and improving its fundamentals. The recent market correction has created attractive entry points and three new companies have already been added to BB Biotech's portfolio. In keeping with its stated dividend policy over the past several years, the Board of Directors' dividend proposal at the upcoming Annual General Meeting of shareholders on March 21, 2019 - an ordinary dividend of CHF 3.05 per share - corresponds to a 5% return on the volume-weighted average closing price of BB Biotech shares in December of 2018. *
All major global equity indices declined in 2018, due to fears of a global economic slowdown associated with US-China trade disputes and concern about tightening US fiscal policy. The European Union endured Brexit woes and government budget concerns practically all year long. The Dow Jones (-3.5% in USD), Nasdaq Composite (-2.8% in USD), DAX (-18.3% in EUR), and SPI (-8.6% in CHF) indices all fell, while the Nasdaq Biotech Index (NBI) lost around -8.9% in USD in 2018. Most of these losses came from a very weak fourth quarter, when most of these benchmarks fell double-digit percentages.
Notwithstanding the general market landscape and the very pessimistic mood as the year came to an end, management observed many positive developments in the year gone by. Fundamental progress was made on the drug development front and across the biotechnology industry during 2018. The FDA approved 18 new drugs in the fourth quarter 2018, bringing the total number of approvals for the year to a record 59. The capital many companies sought to raise, either through IPOs or rights issues, exceeded the inflow of funds into investment vehicles focused on the biotechnology industry. Consequently, many of the capital-raising transactions in 2018 were conducted under unfavorable conditions. Nevertheless, most of the proposed transactions were successfully completed because the fundamental progress of new technologies and the underlying market needs remain exciting and valuable. The correction in the valuations of almost all biotechnology companies may bring new opportunities for value growth and dispositions in 2019.
*Strong shareholder support underpins BB Biotech's relative stability in FY 2018*
For 2018, BB Biotech's total return of -5.2% in CHF and -2.2% in EUR was less than the underlying portfolio due to continued strong shareholder support. Weakening of the EUR over the USD created a tailwind for Euro-denominated performance. The portfolio Net Asset Value (NAV) declined -14.5% in CHF, -11.1% in EUR and -15.0% in USD.
For the fourth quarter, BB Biotech's share price declined -18.8% in CHF and -17.2% in EUR. Since the inclusion into the SPI and SMIM Index on September 24, 2018, additional demand for BB Biotech shares has amplified short-term volatility, which added to the effects of weak market conditions. BB Biotech's portfolio NAV for the same period traced the overall market decline at -18.2% in CHF, -17.3% in EUR and -18.2% in USD. The portfolio performance was favorable relative to the overall broad NBI benchmark in this most difficult fourth quarter.
Consolidated, but not yet audited fourth quarter 2018 data indicate a net loss of CHF 643 mn versus last year's loss of CHF 156 mn. Consolidated, but not yet audited full year 2018 data showed a net loss of CHF 471 mn compared to a net gain of CHF 688 mn for the full year of 2017.
*A proposed dividend of CHF 3.05 per share*
The Board of Directors will propose a regular dividend of CHF 3.05 per share at the general assembly on March 21, 2019. This is computed as a 5% dividend yield applied to the average share price of December 2018 - consistent with the dividend policy introduced in 2013.
*Portfolio adjustments in the fourth quarter 2018*
In the fourth quarter, BB Biotech exited three positions. First, after building a stake in Tesaro at distressed valuation levels, it gained from Glaxo Smith Kline's acquisition price of USD 75 per share (approximately USD 5 bn for the company). The entire position was sold at the time the transaction documents were released, which generated approximately 8% cash for the portfolio, and a substantial profit at a time when equity markets were under substantial pressure. Second and third, the remaining holdings in Novo Nordisk and Achillion were sold. Early in the fourth quarter further profits were taken on other large cap investments, Celgene, Gilead and Regeneron, which were then reinvested as part of the announced strategic portfolio reallocation - focusing more on existing smaller and mid cap portfolio companies and some promising new positions. BB Biotech took advantage of market conditions by investing more in existing mid cap companies such as Neurocrine, Agios, Alnylam and Sage at attractive valuations, and by increasing the stake in Argenx, Nektar, Myokardia and G1 Therapeutics. It also invested capital in Moderna Therapeutics, both in their record-breaking IPO of USD 600 mn and in the post-IPO opportunity created by a sell-off that drove share prices lower.
An investment was made in Kezar, a company new to BB Biotech, focusing on autoimmune disorders. The company's lead program, KZR-616, is a first-in-class immunoproteasome inhibitor about to be tested in Phase II trials in lupus nephritis patients.
Following a comprehensive review of the genetic therapy landscape, in line with BB Biotech's strategy to reinvest more in earlier stage leaders, capital was invested in Sangamo and Audentes. Sangamo has improved zinc finger nuclease technology for gene therapy over more than two decades and is advancing multiple fully-owned projects as well as partnered programs. Audentes has four gene therapies in clinical development. Their lead program is AT-132, an adeno-associated virus carrying the MTM1 gene for long-term expression of myotubularin in muscle cells for newborns with X-linked myotubular myopathy disease.
*Outlook for 2019 - sector fundamentals exciting, very attractive valuation levels, in a continued volatile environment*
BB Biotech believes that 2019 will continue to bring important technology progress allowing new drug modalities to address many unmet medical needs in future years. Thus, the management team's asset allocation will not only center around established areas - such as oncology, orphan diseases and neurological indications - but will also focus on rapidly emerging technologies which can offer novel drug modalities which promise the best therapeutic profile and economic value.
For example, BB Biotech believes that RNA-based medicines - currently in early adoption for rare and serious diseases - will broaden into larger patient populations in the coming years. On the other hand, one-time potentially curative genetic medicines are likely to be applied for the foreseeable future to rare, monogenetic diseases. As it has already done successfully in the past, BB Biotech will continue to add companies performing early-stage clinical development in these areas. With this strategy, BB Biotech's current focus on small molecules and biologics will evolve over time to include newer drug modalities based on technologies its portfolio managers expect to provide high-value medical solutions to seriously sick patients over the coming decade.
With respect to the biotechnology environment, continued debate around value assessment and structural change in the US healthcare system can be expected. This debate has impacted the profit outlook for large and profitable biotechnology and pharmaceutical companies. The decline in valuations during 2018 may force smaller and mid cap biotechnology companies requiring further financing to turn to M&A more readily than before. The surprising takeover of Celgene by Bristol-Myers Squibb for USD 70 bn underpins that even the large capitalized and highly profitable biotechnology companies can become acquisition targets thanks to their very attractive valuation levels. With the transaction expected to consummate in the third quarter of 2019, BB Biotech would close out another long-term and highly successful investment.
These dynamics are welcomed by BB Biotech as a demonstration of the vibrancy of the investment cycle in biotechnology - and the need to remain diligent and focused on value creation for the future. Critically then, the growth case for the biotechnology industry and for BB Biotech's highly selective portfolio companies is as compelling as ever. Management anticipates that 2019 will be another banner year for product approvals as the FDA continues its quest to support innovation. BB Biotech looks forward to exciting news flow from its portfolio companies and believes that mid- and long-term growth in biotechnology will continue to provide an excellent case for investment.The complete annual report as of December 31, 2018, will be published on February 15, 2019.*For further information:*
*Investor Relations*
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch
*Media Relations*
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch
TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch
www.bbbiotech.com*Company profile*
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.*Disclaimer *
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.
*Composition of BB Biotech's portfolio as of December 31, 2018*
(in % of securities, rounded values)
Ionis Pharmaceuticals 15.1%
Incyte 7.8%
Neurocrine Biosciences 7.6%
Vertex Pharmaceuticals 7.3%
Esperion Therapeutics 5.0%
Celgene 4.7%
Agios Pharmaceuticals 4.3%
Sage Therapeutics 4.2%
Alexion Pharmaceuticals 4.1%
Halozyme Therapeutics 3.9%
Alnylam Pharmaceuticals 3.7%
Radius Health 3.5%
Argenx SE 2.7%
Gilead 2.7%
Moderna Therapeutics 2.3%
Akcea Therapeutics 2.3%
Wave Life Sciences 2.0%
Myovant Sciences 1.9%
Intercept Pharmaceuticals 1.9%
Exelixis 1.8%
Nektar Therapeutics 1.5%
Myokardia 1.4%
Macrogenics 1.3%
Scholar Rock Holdings 0.9%
Alder Biopharmaceuticals 0.9%
Voyager Therapeutics 0.9%
Regeneron Pharmaceuticals 0.8%
Intra-Cellular Therapies 0.8%
Kezar Life Sciences 0.6%
Audentes Therapeutics 0.5%
Sangamo Therapeutics 0.5%
Novavax 0.5%
G1 Therapeutics 0.4%
Cidara Therapeutics 0.2%
Radius Health Warrants, 02/19/2019
*Total securities* *CHF 3 064.2 mn*
Other assets CHF 22.6 mn
Other payables CHF (202.3) mn
*Net asset value* *CHF 2 884.5 mn*
--------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=EGCHDUDOVC
Document title: Media release --------------------
18.01.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
End of News DGAP News Service Reported by EQS Group 2 hours ago.
18.01.2019 / 07:00
The issuer is solely responsible for the content of this announcement.
--------------------
Media release as of January 18, 2019
Portfolio of BB Biotech AG as of December 31, 2018
*BB Biotech invests gains of M&A transactions in new technologies - dividend of CHF 3.05 proposed**BB Biotech performed well last year in a the challenging stock market environment. Although its total return was a negative -5.2% in CHF (-2.2% in EUR), this was much better than the portfolio performance of -14.5% in CHF and -11.1% in EUR, which reflects the high level of confidence shareholders have in BB Biotech. During the course of the year BB Biotech realized significant gains on the disposal of three portfolio positions but those gains were unable to completely offset the negative returns from existing major portfolio shareholdings and the generally weak stock market performance. Severe market corrections in December more than erased the gains that BB Biotech had been making over the preceding eleven months. Its shares ended the fourth quarter down -18.8% in CHF and -17.2% in EUR, while its portfolio shed -18.2% of its value in CHF and -17.3% in EUR. BB Biotech incurred a net loss of CHF 643 mn for the fourth quarter and CHF 471 mn for the year as a whole. Management will continue the process of realigning the portfolio to capture future growth trends in the biotech sector. In spite of the unfavorable conditions on financial markets, the biotech sector is making tremendous strides and improving its fundamentals. The recent market correction has created attractive entry points and three new companies have already been added to BB Biotech's portfolio. In keeping with its stated dividend policy over the past several years, the Board of Directors' dividend proposal at the upcoming Annual General Meeting of shareholders on March 21, 2019 - an ordinary dividend of CHF 3.05 per share - corresponds to a 5% return on the volume-weighted average closing price of BB Biotech shares in December of 2018. *
All major global equity indices declined in 2018, due to fears of a global economic slowdown associated with US-China trade disputes and concern about tightening US fiscal policy. The European Union endured Brexit woes and government budget concerns practically all year long. The Dow Jones (-3.5% in USD), Nasdaq Composite (-2.8% in USD), DAX (-18.3% in EUR), and SPI (-8.6% in CHF) indices all fell, while the Nasdaq Biotech Index (NBI) lost around -8.9% in USD in 2018. Most of these losses came from a very weak fourth quarter, when most of these benchmarks fell double-digit percentages.
Notwithstanding the general market landscape and the very pessimistic mood as the year came to an end, management observed many positive developments in the year gone by. Fundamental progress was made on the drug development front and across the biotechnology industry during 2018. The FDA approved 18 new drugs in the fourth quarter 2018, bringing the total number of approvals for the year to a record 59. The capital many companies sought to raise, either through IPOs or rights issues, exceeded the inflow of funds into investment vehicles focused on the biotechnology industry. Consequently, many of the capital-raising transactions in 2018 were conducted under unfavorable conditions. Nevertheless, most of the proposed transactions were successfully completed because the fundamental progress of new technologies and the underlying market needs remain exciting and valuable. The correction in the valuations of almost all biotechnology companies may bring new opportunities for value growth and dispositions in 2019.
*Strong shareholder support underpins BB Biotech's relative stability in FY 2018*
For 2018, BB Biotech's total return of -5.2% in CHF and -2.2% in EUR was less than the underlying portfolio due to continued strong shareholder support. Weakening of the EUR over the USD created a tailwind for Euro-denominated performance. The portfolio Net Asset Value (NAV) declined -14.5% in CHF, -11.1% in EUR and -15.0% in USD.
For the fourth quarter, BB Biotech's share price declined -18.8% in CHF and -17.2% in EUR. Since the inclusion into the SPI and SMIM Index on September 24, 2018, additional demand for BB Biotech shares has amplified short-term volatility, which added to the effects of weak market conditions. BB Biotech's portfolio NAV for the same period traced the overall market decline at -18.2% in CHF, -17.3% in EUR and -18.2% in USD. The portfolio performance was favorable relative to the overall broad NBI benchmark in this most difficult fourth quarter.
Consolidated, but not yet audited fourth quarter 2018 data indicate a net loss of CHF 643 mn versus last year's loss of CHF 156 mn. Consolidated, but not yet audited full year 2018 data showed a net loss of CHF 471 mn compared to a net gain of CHF 688 mn for the full year of 2017.
*A proposed dividend of CHF 3.05 per share*
The Board of Directors will propose a regular dividend of CHF 3.05 per share at the general assembly on March 21, 2019. This is computed as a 5% dividend yield applied to the average share price of December 2018 - consistent with the dividend policy introduced in 2013.
*Portfolio adjustments in the fourth quarter 2018*
In the fourth quarter, BB Biotech exited three positions. First, after building a stake in Tesaro at distressed valuation levels, it gained from Glaxo Smith Kline's acquisition price of USD 75 per share (approximately USD 5 bn for the company). The entire position was sold at the time the transaction documents were released, which generated approximately 8% cash for the portfolio, and a substantial profit at a time when equity markets were under substantial pressure. Second and third, the remaining holdings in Novo Nordisk and Achillion were sold. Early in the fourth quarter further profits were taken on other large cap investments, Celgene, Gilead and Regeneron, which were then reinvested as part of the announced strategic portfolio reallocation - focusing more on existing smaller and mid cap portfolio companies and some promising new positions. BB Biotech took advantage of market conditions by investing more in existing mid cap companies such as Neurocrine, Agios, Alnylam and Sage at attractive valuations, and by increasing the stake in Argenx, Nektar, Myokardia and G1 Therapeutics. It also invested capital in Moderna Therapeutics, both in their record-breaking IPO of USD 600 mn and in the post-IPO opportunity created by a sell-off that drove share prices lower.
An investment was made in Kezar, a company new to BB Biotech, focusing on autoimmune disorders. The company's lead program, KZR-616, is a first-in-class immunoproteasome inhibitor about to be tested in Phase II trials in lupus nephritis patients.
Following a comprehensive review of the genetic therapy landscape, in line with BB Biotech's strategy to reinvest more in earlier stage leaders, capital was invested in Sangamo and Audentes. Sangamo has improved zinc finger nuclease technology for gene therapy over more than two decades and is advancing multiple fully-owned projects as well as partnered programs. Audentes has four gene therapies in clinical development. Their lead program is AT-132, an adeno-associated virus carrying the MTM1 gene for long-term expression of myotubularin in muscle cells for newborns with X-linked myotubular myopathy disease.
*Outlook for 2019 - sector fundamentals exciting, very attractive valuation levels, in a continued volatile environment*
BB Biotech believes that 2019 will continue to bring important technology progress allowing new drug modalities to address many unmet medical needs in future years. Thus, the management team's asset allocation will not only center around established areas - such as oncology, orphan diseases and neurological indications - but will also focus on rapidly emerging technologies which can offer novel drug modalities which promise the best therapeutic profile and economic value.
For example, BB Biotech believes that RNA-based medicines - currently in early adoption for rare and serious diseases - will broaden into larger patient populations in the coming years. On the other hand, one-time potentially curative genetic medicines are likely to be applied for the foreseeable future to rare, monogenetic diseases. As it has already done successfully in the past, BB Biotech will continue to add companies performing early-stage clinical development in these areas. With this strategy, BB Biotech's current focus on small molecules and biologics will evolve over time to include newer drug modalities based on technologies its portfolio managers expect to provide high-value medical solutions to seriously sick patients over the coming decade.
With respect to the biotechnology environment, continued debate around value assessment and structural change in the US healthcare system can be expected. This debate has impacted the profit outlook for large and profitable biotechnology and pharmaceutical companies. The decline in valuations during 2018 may force smaller and mid cap biotechnology companies requiring further financing to turn to M&A more readily than before. The surprising takeover of Celgene by Bristol-Myers Squibb for USD 70 bn underpins that even the large capitalized and highly profitable biotechnology companies can become acquisition targets thanks to their very attractive valuation levels. With the transaction expected to consummate in the third quarter of 2019, BB Biotech would close out another long-term and highly successful investment.
These dynamics are welcomed by BB Biotech as a demonstration of the vibrancy of the investment cycle in biotechnology - and the need to remain diligent and focused on value creation for the future. Critically then, the growth case for the biotechnology industry and for BB Biotech's highly selective portfolio companies is as compelling as ever. Management anticipates that 2019 will be another banner year for product approvals as the FDA continues its quest to support innovation. BB Biotech looks forward to exciting news flow from its portfolio companies and believes that mid- and long-term growth in biotechnology will continue to provide an excellent case for investment.The complete annual report as of December 31, 2018, will be published on February 15, 2019.*For further information:*
*Investor Relations*
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch
*Media Relations*
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch
TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch
www.bbbiotech.com*Company profile*
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.*Disclaimer *
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.
*Composition of BB Biotech's portfolio as of December 31, 2018*
(in % of securities, rounded values)
Ionis Pharmaceuticals 15.1%
Incyte 7.8%
Neurocrine Biosciences 7.6%
Vertex Pharmaceuticals 7.3%
Esperion Therapeutics 5.0%
Celgene 4.7%
Agios Pharmaceuticals 4.3%
Sage Therapeutics 4.2%
Alexion Pharmaceuticals 4.1%
Halozyme Therapeutics 3.9%
Alnylam Pharmaceuticals 3.7%
Radius Health 3.5%
Argenx SE 2.7%
Gilead 2.7%
Moderna Therapeutics 2.3%
Akcea Therapeutics 2.3%
Wave Life Sciences 2.0%
Myovant Sciences 1.9%
Intercept Pharmaceuticals 1.9%
Exelixis 1.8%
Nektar Therapeutics 1.5%
Myokardia 1.4%
Macrogenics 1.3%
Scholar Rock Holdings 0.9%
Alder Biopharmaceuticals 0.9%
Voyager Therapeutics 0.9%
Regeneron Pharmaceuticals 0.8%
Intra-Cellular Therapies 0.8%
Kezar Life Sciences 0.6%
Audentes Therapeutics 0.5%
Sangamo Therapeutics 0.5%
Novavax 0.5%
G1 Therapeutics 0.4%
Cidara Therapeutics 0.2%
Radius Health Warrants, 02/19/2019
*Total securities* *CHF 3 064.2 mn*
Other assets CHF 22.6 mn
Other payables CHF (202.3) mn
*Net asset value* *CHF 2 884.5 mn*
--------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=EGCHDUDOVC
Document title: Media release --------------------
18.01.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
End of News DGAP News Service Reported by EQS Group 2 hours ago.
↧
5 routes under UDAN scheme to restart from Feb 13 in Maharashtra
In a boost to low-cost air travel in Maharashtra, five routes under the Centre's UDAN scheme, which were discontinued some time back, will resume on February 13
Reported by DNA 2 hours ago.
↧
Business groups urge RBI to cut interest rate by at least half a percentage point, lower cash reserve ratio
RBI Governor Shaktikanta Das, who took charge last month after the sudden exit of Urjit Patel, was presented with the requests when he met industry captains in Mumbai ahead of the next monetary policy meeting on 7 February.
Reported by Firstpost 2 hours ago.
↧
Jeff Bezos and Lauren Sanchez will attend the Oscars together, sources say
The inseparable pair will appear at a number of events in the coming months, including the February 24 Oscars ceremony.
Reported by MailOnline 1 hour ago.
↧
↧
Sri Lanka Cricket elections postponed to Feb 21
[UK], Jan 18 (ANI): Sri Lanka Cricket elections have been postponed by two weeks and will now be held on February 21. Earlier, the scheduled date for election was February 7.
Reported by Sify 2 hours ago.
↧
Total Dhamaal first poster out; trailer of Anil Kapoor, Madhuri Dixit, Ajay Devgn starrer to come out on this date — Check out
The film is all set to hit the screens on February 22, 2019.
Reported by Zee News 2 hours ago.
↧
Providence Resources P.l.c. - Licence Update - Avalon - Approval of Conversion to Frontier Exploration Licence 2/19
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
*LICENCE UPDATE*
*AVALON*
*APPROVAL OF CONVERSION TO FRONTIER EXPLORATION LICENCE 2/19*
*Dublin and London – January 18, 2019 - *Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based Oil and Gas Exploration Company (the “*Company*”), today provides an update on Licensing Option (“*LO*”) 16/27, operated by *TOTAL E&P Ireland B.V. (“TOTAL”) *(50.0%) on behalf of its partners, Providence Resources P.l.c. (40.0%) and Sosina Exploration Limited (10.0%), collectively referred to as the “*JV Partners*”. LO 16/27 is located in the southern Porcupine Basin offshore Ireland and contains the undrilled Paleocene “Avalon” exploration prospect.
The JV Partners recently applied to convert LO 16/27 to a Frontier Exploration Licence (“*FEL*”) and are pleased to confirm that the Minister of State at the Department of Communications, Climate Action and Environment has now confirmed approval for the JV partners to convert LO 16/27 to FEL 2/19, with effect from February 1, 2019.
Pursuant to the terms of a Farm-out Agreement agreed between the JV partners in June 2017, in the event that a decision is taken to drill an exploration well on Avalon, TOTAL will pay 60% of the drilling costs, subject to a gross well cap of
US$ 42 million.
Dr John O’Sullivan, Technical Director at Providence, said:
“We are very pleased to confirm approval from the Minister to progress the Avalon Licensing Option to Frontier Exploration Licence status. Avalon is a very large and exciting prospect, which lies adjacent to Dunquin North, and the JV Partners look forward to progressing it further under the Operatorship of TOTAL.”
*INVESTOR ENQUIRIES*
*Providence Resources P.l.c.* Tel: +353 1 219 4074
Tony O’Reilly, Chief Executive Officer
John O’Sullivan, Technical Director
*Cenkos Securities plc* Tel: +44 131 220 9771
Neil McDonald/Derrick Lee
*J&E Davy* Tel: +353 1 679 6363
Anthony Farrell
*Mirabaud Securities Limited* Tel: + 44 20 3167 7221
Peter Krens
*MEDIA ENQUIRIES*
*Powerscourt* Tel: +44 207 250 1446
Peter Ogden
*Murray Consultants* Tel: +353 1 498 0300
Pauline McAlester
*ABOUT PROVIDENCE RESOURCES*
Providence Resources is an Irish based Oil & Gas Exploration Company with a portfolio of appraisal and exploration assets located offshore Ireland. Providence’s shares are quoted on the AIM in London and the ESM in Dublin.
*ANNOUNCEMENT*
This announcement has been reviewed by Dr John O’Sullivan, Technical Director, Providence Resources P.l.c. John is a geology graduate of University College, Cork and holds a Masters in Applied Geophysics from the National University of Ireland, Galway. He also holds a Masters in Technology Management from the Smurfit Graduate School of Business at University College Dublin and a doctorate in Geology from Trinity College Dublin. John is a Chartered Geologist and a Fellow of the Geological Society of London. He is also a member of the Petroleum Exploration Society of Great Britain, the Society of Petroleum Engineers and the Geophysical Association of Ireland. John has more than 25 years of experience in the oil and gas exploration and production industry having previously worked with both Mobil and Marathon Oil. John is a qualified person as defined in the guidance note for Mining Oil & Gas Companies, March 2006 of the London Stock Exchange. Definitions in this press release are consistent with SPE guidelines. SPE/WPC/AAPG/SPEE Petroleum Resource Management System 2007 has been used in preparing this announcement.
Reported by GlobeNewswire 1 hour ago.
*LICENCE UPDATE*
*AVALON*
*APPROVAL OF CONVERSION TO FRONTIER EXPLORATION LICENCE 2/19*
*Dublin and London – January 18, 2019 - *Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based Oil and Gas Exploration Company (the “*Company*”), today provides an update on Licensing Option (“*LO*”) 16/27, operated by *TOTAL E&P Ireland B.V. (“TOTAL”) *(50.0%) on behalf of its partners, Providence Resources P.l.c. (40.0%) and Sosina Exploration Limited (10.0%), collectively referred to as the “*JV Partners*”. LO 16/27 is located in the southern Porcupine Basin offshore Ireland and contains the undrilled Paleocene “Avalon” exploration prospect.
The JV Partners recently applied to convert LO 16/27 to a Frontier Exploration Licence (“*FEL*”) and are pleased to confirm that the Minister of State at the Department of Communications, Climate Action and Environment has now confirmed approval for the JV partners to convert LO 16/27 to FEL 2/19, with effect from February 1, 2019.
Pursuant to the terms of a Farm-out Agreement agreed between the JV partners in June 2017, in the event that a decision is taken to drill an exploration well on Avalon, TOTAL will pay 60% of the drilling costs, subject to a gross well cap of
US$ 42 million.
Dr John O’Sullivan, Technical Director at Providence, said:
“We are very pleased to confirm approval from the Minister to progress the Avalon Licensing Option to Frontier Exploration Licence status. Avalon is a very large and exciting prospect, which lies adjacent to Dunquin North, and the JV Partners look forward to progressing it further under the Operatorship of TOTAL.”
*INVESTOR ENQUIRIES*
*Providence Resources P.l.c.* Tel: +353 1 219 4074
Tony O’Reilly, Chief Executive Officer
John O’Sullivan, Technical Director
*Cenkos Securities plc* Tel: +44 131 220 9771
Neil McDonald/Derrick Lee
*J&E Davy* Tel: +353 1 679 6363
Anthony Farrell
*Mirabaud Securities Limited* Tel: + 44 20 3167 7221
Peter Krens
*MEDIA ENQUIRIES*
*Powerscourt* Tel: +44 207 250 1446
Peter Ogden
*Murray Consultants* Tel: +353 1 498 0300
Pauline McAlester
*ABOUT PROVIDENCE RESOURCES*
Providence Resources is an Irish based Oil & Gas Exploration Company with a portfolio of appraisal and exploration assets located offshore Ireland. Providence’s shares are quoted on the AIM in London and the ESM in Dublin.
*ANNOUNCEMENT*
This announcement has been reviewed by Dr John O’Sullivan, Technical Director, Providence Resources P.l.c. John is a geology graduate of University College, Cork and holds a Masters in Applied Geophysics from the National University of Ireland, Galway. He also holds a Masters in Technology Management from the Smurfit Graduate School of Business at University College Dublin and a doctorate in Geology from Trinity College Dublin. John is a Chartered Geologist and a Fellow of the Geological Society of London. He is also a member of the Petroleum Exploration Society of Great Britain, the Society of Petroleum Engineers and the Geophysical Association of Ireland. John has more than 25 years of experience in the oil and gas exploration and production industry having previously worked with both Mobil and Marathon Oil. John is a qualified person as defined in the guidance note for Mining Oil & Gas Companies, March 2006 of the London Stock Exchange. Definitions in this press release are consistent with SPE guidelines. SPE/WPC/AAPG/SPEE Petroleum Resource Management System 2007 has been used in preparing this announcement.
Reported by GlobeNewswire 1 hour ago.
↧
Xbrane Biopharma announces acceptance of initiation of Xlucane clinical trial in the US
*Press release*
*2019-01-18*
*The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial with Xlucane, a ranibizumab (Lucentis*®*) biosimilar candidate. *
"It is with great satisfaction we can announce acceptance from the FDA and the Central Ethics Committee to initiate the Xplore trial. Applications to the additional countries are being submitted continuously during January and February. First patient in is expected for March 2019.", says CEO Martin Åmark.
*About the **Xplore trial*
The Xplore trial is a phase III trial designed to confirm biosimilarity with regards to safety, efficacy and immunogenicity of Xlucane versus Lucentis® in patients with wet form of age-related macular degeneration (wAMD). The study design was developed in consultation with the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA). The primary efficacy end-point of the trial is change in visual acuity after eight weeks of treatment, for which the confidence interval of the difference between Xlucane and Lucentis® needs to fall within a pre-defined equivalence margin. In addition, several secondary endpoints related to efficacy, safety and immunogenicity are followed over the full treatment period of 12 months. The study will involve approx. 600 patients across approx. 150 sites in 16 countries and is expected to support the registration of Xlucane across majority of regions globally. Xbrane has for the Xplore trial contracted the global CRO Syneos Health which has conducted some of the largest trials in recent years in the wAMD patient population. Xbrane will communicate in relation to the progress of the trial at following milestones: first patient in, last patient in, top-line data on the primary endpoint and final study report.
*About Xlucane*
Xlucane is a ranibizumab (Lucentis®) biosimilar candidate developed by Xbrane Biopharma. Xlucane has demonstrated high analytical similarity compared to Lucentis® in a panel of methods in accordance with requirements from EMA and FDA as well as equivalent pharmacokinetic profile and tolerability in-vivo compared to Lucentis®. Xbrane has entered a co-development agreement with STADA Arzneimittel AG regarding Xlucane under which the companies finance the continued development of the product 50/50 and will share the profits from sales and marketing of the product 50/50.
*For further information, please contact:*
Martin Åmark
Chief Executive Officer
M: +46(0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
*About Xbrane *
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB (corp@avanza.se, +46 (0)8 409 421 20) is Xbrane's certified adviser. For more information see www.xbrane.com.
This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18 January 8:00.
*Attachment*
· Acceptance for initiation of Xplore.pdf Reported by GlobeNewswire 1 hour ago.
*2019-01-18*
*The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial with Xlucane, a ranibizumab (Lucentis*®*) biosimilar candidate. *
"It is with great satisfaction we can announce acceptance from the FDA and the Central Ethics Committee to initiate the Xplore trial. Applications to the additional countries are being submitted continuously during January and February. First patient in is expected for March 2019.", says CEO Martin Åmark.
*About the **Xplore trial*
The Xplore trial is a phase III trial designed to confirm biosimilarity with regards to safety, efficacy and immunogenicity of Xlucane versus Lucentis® in patients with wet form of age-related macular degeneration (wAMD). The study design was developed in consultation with the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA). The primary efficacy end-point of the trial is change in visual acuity after eight weeks of treatment, for which the confidence interval of the difference between Xlucane and Lucentis® needs to fall within a pre-defined equivalence margin. In addition, several secondary endpoints related to efficacy, safety and immunogenicity are followed over the full treatment period of 12 months. The study will involve approx. 600 patients across approx. 150 sites in 16 countries and is expected to support the registration of Xlucane across majority of regions globally. Xbrane has for the Xplore trial contracted the global CRO Syneos Health which has conducted some of the largest trials in recent years in the wAMD patient population. Xbrane will communicate in relation to the progress of the trial at following milestones: first patient in, last patient in, top-line data on the primary endpoint and final study report.
*About Xlucane*
Xlucane is a ranibizumab (Lucentis®) biosimilar candidate developed by Xbrane Biopharma. Xlucane has demonstrated high analytical similarity compared to Lucentis® in a panel of methods in accordance with requirements from EMA and FDA as well as equivalent pharmacokinetic profile and tolerability in-vivo compared to Lucentis®. Xbrane has entered a co-development agreement with STADA Arzneimittel AG regarding Xlucane under which the companies finance the continued development of the product 50/50 and will share the profits from sales and marketing of the product 50/50.
*For further information, please contact:*
Martin Åmark
Chief Executive Officer
M: +46(0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
*About Xbrane *
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB (corp@avanza.se, +46 (0)8 409 421 20) is Xbrane's certified adviser. For more information see www.xbrane.com.
This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18 January 8:00.
*Attachment*
· Acceptance for initiation of Xplore.pdf Reported by GlobeNewswire 1 hour ago.
↧
↧
ALOHA’s 3rd Annual National Math Competition for Kids Offers Over $43,000 in Cash Prizes; Sign up Continues Thru Feb. 15, 2019
Registration open to children (grades 1-6) January through February 15, 2019 for ALOHA’s 3rd Annual National Math Challenge for kids with over $43,000 in cash prizes. This math test-based competition for kids is open to students grades 1-6 nationally;* https://alohamathchallenge.com.
EDISON, N.J. (PRWEB) January 18, 2019
Registration for ALOHA’s 3rd Annual National Math Challenge for kids, offering over $43,000 in cash prizes, is open to children (grades 1-6) through February 15, 2019. This math test-based competition for kids is open to students grades 1-6 nationally.* Sign up continues through Feb.15, 2019 click for more info.
ALOHA’s 2019 National Math Challenge features three separate age categories with 5 cash prize winners in each category. Cash prizes will total more than $43,000. Over 1,300 students participated last year in ALOHA’s 2nd Annual National Math Challenge. Each student registered for the 2019 Challenge will compete within their age group across three rounds of testing. The preliminary test round will be held March 16, 2019. Qualifying students will be invited to compete in the semi-finals on Apr 13, and qualifying finalists will be invited to the final round held in Edison NJ in May, 2019.** Registration fee for contest: For current ALOHA students: $45 for the first child, for non-ALOHA students, $60*; sibling discounts available. Registration is open through February 15, 2019. Click/tap here to register.
How Does This National Math Challenge Work?
Students will compete in three categories: Pre-Jr: grades 1& 2; Jr: grades 3 & 4 and Sr: grades 5 & 6. The math challenge is open to all students, not just to those enrolled in an ALOHA program, although there are some state restrictions* (see eligibility information below). Children will be tested with competitive math-type questions that are grade level appropriate. Students will not be allowed to use calculators or an abacus. Scratch note paper and pencils will be allowed.
ALOHA Mind Math National Challenge Prizes:· Pre-Junior Challenge (Grades 1-2)
1st Prize: $5,000; 2nd Prize: $2,000; 3rd Prize: $1,000; 4th Prize: $750; 5th Prize: $500.· Junior Challenge (Grades 3-4)
1st Prize: $7,500; 2nd Prize: $3,000; 3rd Prize: $1,500; 4th Prize: $1,000; 5th Prize: $750.· Senior Challenge (Grades 5-6)
1st Prize: $10,000; 2nd Prize: $5,000; 3rd Prize: $2,500; 4th Prize: $1,500; 5th Prize: $1,000.
*Some restrictions apply, please see contest eligibility information below and full rules and regulations at: https://alohamathchallenge.com/math-challenge-rules/
** Final Round Entrants and their Eligible Children must travel to Edison, New Jersey to compete in the Final Round. See complete details in the contest rules and regulations.
How Can a Child Get Involved in ALOHA Programs?
ALOHA currently works with children in grades K through 6th in Math, Reading and Writing at over 100 locations in 19 states across the U.S., including: AL, AR, AZ, CA, CT, FL, GA, IL, MA, MI, MO, NC, NH, NJ, NY, OH, PA, TX, VA. For more details on these programs, go to http://ALOHAMindMath.com, search for a nearby center using ALOHA's online center locator, check the ALOHA Facebook page (Facebook.com/aloha.usa), or call 877-256-4203 to find a center near you. Each ALOHA learning center is independently owned and operated.
About ALOHA
Since 2006, ALOHA Mind Math, a leading provider of mental arithmetic and English Reading | Writing after school programs, has been helping children in the U.S. between the ages of 3 through 12 achieve academic excellence. Other programs also include a Tiny Thinkers pre-school program for ages 3-5 and Math and Reading Summer Camps. The interactive learning process ALOHA uses enhances a child’s math, reading and writing capabilities. Teachers also assist children in developing skills and abilities such as critical thinking, observation, and listening that result in the overall growth of the child. The ALOHA program is also in use in 20 countries worldwide.
*Math Challenge Eligibility
The ALOHA® National Math Challenge (the “Contest”) is open to legal residents of the United States except where our contest is not permitted by the laws of Colorado & North Dakota, and as such no Entrants will be accepted in these states or in any other jurisdiction where this Contest is not permitted by applicable law. All registrants must be a parent or legal guardian of a child that is in grades one (1) through six (6) (“Eligible Child” or, collectively, “Eligible Children”). Also, due to state laws, legal residents of Arizona, Connecticut, Georgia, Illinois and Maryland may only participate if they are currently a parent or a guardian of a child that is enrolled in programs at an ALOHA Learning center and is currently in grades one (1) through six (6) and (“Eligible Child” or, collectively, “Eligible Children”). Employees (and their immediate families or those living in the same household) of Apogee Learning, LLC (“Sponsor”) or any of its affiliates, subsidiaries, divisions, parent and related companies, franchisees, suppliers, printers and advertising, promotional and judging agencies (collectively, “Sponsor Affiliates”) are not eligible to enter or win. Parents or legal guardians wanting their child to participate in the Contest may do so by registering an Eligible Child in accordance with the complete rules and eligibility page (https://alohamathchallenge.com/math-challenge-rules/) before the Contest registration end date. Reported by PRWeb 28 minutes ago.
EDISON, N.J. (PRWEB) January 18, 2019
Registration for ALOHA’s 3rd Annual National Math Challenge for kids, offering over $43,000 in cash prizes, is open to children (grades 1-6) through February 15, 2019. This math test-based competition for kids is open to students grades 1-6 nationally.* Sign up continues through Feb.15, 2019 click for more info.
ALOHA’s 2019 National Math Challenge features three separate age categories with 5 cash prize winners in each category. Cash prizes will total more than $43,000. Over 1,300 students participated last year in ALOHA’s 2nd Annual National Math Challenge. Each student registered for the 2019 Challenge will compete within their age group across three rounds of testing. The preliminary test round will be held March 16, 2019. Qualifying students will be invited to compete in the semi-finals on Apr 13, and qualifying finalists will be invited to the final round held in Edison NJ in May, 2019.** Registration fee for contest: For current ALOHA students: $45 for the first child, for non-ALOHA students, $60*; sibling discounts available. Registration is open through February 15, 2019. Click/tap here to register.
How Does This National Math Challenge Work?
Students will compete in three categories: Pre-Jr: grades 1& 2; Jr: grades 3 & 4 and Sr: grades 5 & 6. The math challenge is open to all students, not just to those enrolled in an ALOHA program, although there are some state restrictions* (see eligibility information below). Children will be tested with competitive math-type questions that are grade level appropriate. Students will not be allowed to use calculators or an abacus. Scratch note paper and pencils will be allowed.
ALOHA Mind Math National Challenge Prizes:· Pre-Junior Challenge (Grades 1-2)
1st Prize: $5,000; 2nd Prize: $2,000; 3rd Prize: $1,000; 4th Prize: $750; 5th Prize: $500.· Junior Challenge (Grades 3-4)
1st Prize: $7,500; 2nd Prize: $3,000; 3rd Prize: $1,500; 4th Prize: $1,000; 5th Prize: $750.· Senior Challenge (Grades 5-6)
1st Prize: $10,000; 2nd Prize: $5,000; 3rd Prize: $2,500; 4th Prize: $1,500; 5th Prize: $1,000.
*Some restrictions apply, please see contest eligibility information below and full rules and regulations at: https://alohamathchallenge.com/math-challenge-rules/
** Final Round Entrants and their Eligible Children must travel to Edison, New Jersey to compete in the Final Round. See complete details in the contest rules and regulations.
How Can a Child Get Involved in ALOHA Programs?
ALOHA currently works with children in grades K through 6th in Math, Reading and Writing at over 100 locations in 19 states across the U.S., including: AL, AR, AZ, CA, CT, FL, GA, IL, MA, MI, MO, NC, NH, NJ, NY, OH, PA, TX, VA. For more details on these programs, go to http://ALOHAMindMath.com, search for a nearby center using ALOHA's online center locator, check the ALOHA Facebook page (Facebook.com/aloha.usa), or call 877-256-4203 to find a center near you. Each ALOHA learning center is independently owned and operated.
About ALOHA
Since 2006, ALOHA Mind Math, a leading provider of mental arithmetic and English Reading | Writing after school programs, has been helping children in the U.S. between the ages of 3 through 12 achieve academic excellence. Other programs also include a Tiny Thinkers pre-school program for ages 3-5 and Math and Reading Summer Camps. The interactive learning process ALOHA uses enhances a child’s math, reading and writing capabilities. Teachers also assist children in developing skills and abilities such as critical thinking, observation, and listening that result in the overall growth of the child. The ALOHA program is also in use in 20 countries worldwide.
*Math Challenge Eligibility
The ALOHA® National Math Challenge (the “Contest”) is open to legal residents of the United States except where our contest is not permitted by the laws of Colorado & North Dakota, and as such no Entrants will be accepted in these states or in any other jurisdiction where this Contest is not permitted by applicable law. All registrants must be a parent or legal guardian of a child that is in grades one (1) through six (6) (“Eligible Child” or, collectively, “Eligible Children”). Also, due to state laws, legal residents of Arizona, Connecticut, Georgia, Illinois and Maryland may only participate if they are currently a parent or a guardian of a child that is enrolled in programs at an ALOHA Learning center and is currently in grades one (1) through six (6) and (“Eligible Child” or, collectively, “Eligible Children”). Employees (and their immediate families or those living in the same household) of Apogee Learning, LLC (“Sponsor”) or any of its affiliates, subsidiaries, divisions, parent and related companies, franchisees, suppliers, printers and advertising, promotional and judging agencies (collectively, “Sponsor Affiliates”) are not eligible to enter or win. Parents or legal guardians wanting their child to participate in the Contest may do so by registering an Eligible Child in accordance with the complete rules and eligibility page (https://alohamathchallenge.com/math-challenge-rules/) before the Contest registration end date. Reported by PRWeb 28 minutes ago.
↧
Mexus Stage 1 drilling complete
*Mexus Pays off $105,000 loan commitment**Mexus Gold plans to reach out to Itronics and explore its breakthrough technology*
CABORCA, Mexico, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Mexus Gold US (OTCQB: MXSG) (“Mexus” or the “Company) today announced that the 1^st phase of drilling is now complete at its Santa Elena mine. The company is awaiting assay results which will be plotted and produce a 3D Model used for interpretation. The final results are expected in February 2019. The company has received results for holes 6 thru 9 which aimed to intercept the Julio vein at depths between 60 to 100 meters. The Julio structure is consistent at depth with mineralized widths of 2 to 5 meters. All quartz vein intercepts had gold and silver noticeable with .1 to .3 g/t Au as the tracing values and 2 to 10 g/t Au as the high values. Hole 7 is the best evidence of high-grade gold at 9.89 g/t Au with an attractive width of 5.3 meters and an overall average of 3.12 g/t Au.* *
Hole Intercept (M) Au (g/t) Ag (g/t)
1 1 .19 .75
2 1 *6.28* 21.3
3 1 .27 .38
4 3 .7 .5
5 2 .79 5
6 1 .31 .5
7 5.3 *3.12* 9
8 1.5 .22 .5
9 .5 .1 .5
Average *1.8* *1.3* *4.3*
The resulting Julio quartz vein section drilled contained a slope distance of 180 meters with an average width of 1.8 meters and a strike distance of 275 meters accumulating approximately 180,000 tons with average grades of 1.3 g/t Au and 4.3 g/t Ag. This includes all quartz material without being selective. Approximately 7500 oz. of gold are contained in this section of the Julio quartz vein and about 25,000 oz of silver. Another 200 meters of this quartz vein is minable to the north and about 800 meters to the south of the studied area. Selective mining can be directed based on sampling production drilling used for blasting. The apparent shear zone associated with the Julio vein seems to be a post-mineral event and is parallel to the quartz vein using the structure as a brittle thrust plane. The Julio offset structure was intercepted on hole 1 near the surface with .2 g/t Au and traces of silver making it a viable target for further exploration. All surface sampling data will be processed together with drilling data to identify the best production areas of the structures and understand structural geology of low angle shear zones. Exploration will now continue to accumulate tonnage from new shear zones and quartz vein systems to the south and will include production drilling and surface sampling.
The first stage drilling results gives Mexus the tonnage and values needed to proceed with a mining plan that includes stage 2 drilling. The company plans to build upon its resources from stage 1 by commencing a 12,000 ton per month quartz vein production. Mexus expects the 12,000 ton per month production to produce 500 plus ounces of gold and 1,600 ounces of silver. This small but significant production will fund stage 2 drilling along with advancing Mexus’ other goals.
Mexus will begin preparing the heap leach in the near term. The plan is to remove material from the front of the pad and replace it with fresh ore. This new ore will be carefully controlled to keep the highest grades possible on the pad. Mexus CEO Paul Thompson added “The goal is to start with a small production and build out as additional drilling results become available. Mexus now has a group of financial experts who will assist the company in achieving its goals.”
About Mexus Gold US
Mexus Gold US is an American based mining company with holdings in Mexico. The fully owned Santa Elena mine is located 54km NW of Caborca, Mexico. Mexus also owns rights to the Ures property located 80km N of Hermosillo, Mexico. This property contains 6900 acres and has both gold and copper on the property. Founded in 2009, Mexus Gold US is committed to protecting the environment, mine safety and employing members of the communities in which it operates.
For more information on Mexus Gold US, visit *www.mexusgoldus.com*. 775-722-6171
Cautionary Statement
Forward looking Statement: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. Reported by GlobeNewswire 18 minutes ago.
CABORCA, Mexico, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Mexus Gold US (OTCQB: MXSG) (“Mexus” or the “Company) today announced that the 1^st phase of drilling is now complete at its Santa Elena mine. The company is awaiting assay results which will be plotted and produce a 3D Model used for interpretation. The final results are expected in February 2019. The company has received results for holes 6 thru 9 which aimed to intercept the Julio vein at depths between 60 to 100 meters. The Julio structure is consistent at depth with mineralized widths of 2 to 5 meters. All quartz vein intercepts had gold and silver noticeable with .1 to .3 g/t Au as the tracing values and 2 to 10 g/t Au as the high values. Hole 7 is the best evidence of high-grade gold at 9.89 g/t Au with an attractive width of 5.3 meters and an overall average of 3.12 g/t Au.* *
Hole Intercept (M) Au (g/t) Ag (g/t)
1 1 .19 .75
2 1 *6.28* 21.3
3 1 .27 .38
4 3 .7 .5
5 2 .79 5
6 1 .31 .5
7 5.3 *3.12* 9
8 1.5 .22 .5
9 .5 .1 .5
Average *1.8* *1.3* *4.3*
The resulting Julio quartz vein section drilled contained a slope distance of 180 meters with an average width of 1.8 meters and a strike distance of 275 meters accumulating approximately 180,000 tons with average grades of 1.3 g/t Au and 4.3 g/t Ag. This includes all quartz material without being selective. Approximately 7500 oz. of gold are contained in this section of the Julio quartz vein and about 25,000 oz of silver. Another 200 meters of this quartz vein is minable to the north and about 800 meters to the south of the studied area. Selective mining can be directed based on sampling production drilling used for blasting. The apparent shear zone associated with the Julio vein seems to be a post-mineral event and is parallel to the quartz vein using the structure as a brittle thrust plane. The Julio offset structure was intercepted on hole 1 near the surface with .2 g/t Au and traces of silver making it a viable target for further exploration. All surface sampling data will be processed together with drilling data to identify the best production areas of the structures and understand structural geology of low angle shear zones. Exploration will now continue to accumulate tonnage from new shear zones and quartz vein systems to the south and will include production drilling and surface sampling.
The first stage drilling results gives Mexus the tonnage and values needed to proceed with a mining plan that includes stage 2 drilling. The company plans to build upon its resources from stage 1 by commencing a 12,000 ton per month quartz vein production. Mexus expects the 12,000 ton per month production to produce 500 plus ounces of gold and 1,600 ounces of silver. This small but significant production will fund stage 2 drilling along with advancing Mexus’ other goals.
Mexus will begin preparing the heap leach in the near term. The plan is to remove material from the front of the pad and replace it with fresh ore. This new ore will be carefully controlled to keep the highest grades possible on the pad. Mexus CEO Paul Thompson added “The goal is to start with a small production and build out as additional drilling results become available. Mexus now has a group of financial experts who will assist the company in achieving its goals.”
About Mexus Gold US
Mexus Gold US is an American based mining company with holdings in Mexico. The fully owned Santa Elena mine is located 54km NW of Caborca, Mexico. Mexus also owns rights to the Ures property located 80km N of Hermosillo, Mexico. This property contains 6900 acres and has both gold and copper on the property. Founded in 2009, Mexus Gold US is committed to protecting the environment, mine safety and employing members of the communities in which it operates.
For more information on Mexus Gold US, visit *www.mexusgoldus.com*. 775-722-6171
Cautionary Statement
Forward looking Statement: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. Reported by GlobeNewswire 18 minutes ago.
↧
AAITF will take place in Shenzhen, China in February 2019
-The exhibition will highlight over 3,000 brands, 18,000 new products and 30 high-end automotive industry activities and attract industry insiders from around the world
SHENZHEN, China, Jan. 18, 2019 /PRNewswire/ -- AAITF, Automotive Aftermarket Industry and Tuning Trade Fair-Exclusive Global Auto Aftermarket Trade Platform, will be held from Feb. 27 to March 1, 2019 at the Shenzhen Convention and Exhibition Center. In this exhibition, there will be over 3,000 brands, 18,000 new products and 30 high-end automotive industry activities which will attract over 100,000 visitors to the 3-day show. AAITF displays a complete range of the most up-to-date aftermarket products. The show represents the rapid development of automotive aftermarket trends, and covers a variety of categories including OEM, aftermarket, overseas market and emerging channels. The vast onsite exhibit line-up verifies AAITF's strong industrial influence within the field. AAITF sponsored by Guangzhou Jiuzhou Tarsus Exhibition Co., Ltd.
Since making its debut in 2006, AAITF has been successfully held 17 times. This biannual show will cover 120,000 m^2, occupying all the exhibition halls of the venue. AAITF organizing committee also announced that AAITF will be the first show for the new venue in Shenzhen in 2020 and is planning to double its size within 5 years from now.
*The highlights of AAITF 2019:*
*New Products *
A 3-day visit to AAITF 2019 will provide visitors with an abundance of knowledge about the latest aftermarket products from over 3,000 mainstream brand exhibitors, the majority of which were part of the brands' headquarters, coupled with over 18,000 varieties of new products on show all under one roof made for a truly exciting show.
*New Models *
AAITF 2019 will offer a variety of industrial conferences, seminars, forums and workshops for business networking and new business development. These sessions will ensure that all attendees walking away with new ideas and solutions to implement into their current business. Alongside this, the new products exhibited in AAITF will account for 85% of new products within the entire industry, showcasing the latest models within the automotive aftermarket.
*New Trends *
AAITF 2019 will also display the new trends in this industry: the new products dominating the automotive aftermarket, the latest trends to look out for in the industry, the most effective shortcuts to expand the market share.
For more information, please visit the website: www.aaitf.org/en
Related Links :
http://www.aaitf.org/en Reported by PR Newswire Asia 5 minutes ago.
SHENZHEN, China, Jan. 18, 2019 /PRNewswire/ -- AAITF, Automotive Aftermarket Industry and Tuning Trade Fair-Exclusive Global Auto Aftermarket Trade Platform, will be held from Feb. 27 to March 1, 2019 at the Shenzhen Convention and Exhibition Center. In this exhibition, there will be over 3,000 brands, 18,000 new products and 30 high-end automotive industry activities which will attract over 100,000 visitors to the 3-day show. AAITF displays a complete range of the most up-to-date aftermarket products. The show represents the rapid development of automotive aftermarket trends, and covers a variety of categories including OEM, aftermarket, overseas market and emerging channels. The vast onsite exhibit line-up verifies AAITF's strong industrial influence within the field. AAITF sponsored by Guangzhou Jiuzhou Tarsus Exhibition Co., Ltd.
Since making its debut in 2006, AAITF has been successfully held 17 times. This biannual show will cover 120,000 m^2, occupying all the exhibition halls of the venue. AAITF organizing committee also announced that AAITF will be the first show for the new venue in Shenzhen in 2020 and is planning to double its size within 5 years from now.
*The highlights of AAITF 2019:*
*New Products *
A 3-day visit to AAITF 2019 will provide visitors with an abundance of knowledge about the latest aftermarket products from over 3,000 mainstream brand exhibitors, the majority of which were part of the brands' headquarters, coupled with over 18,000 varieties of new products on show all under one roof made for a truly exciting show.
*New Models *
AAITF 2019 will offer a variety of industrial conferences, seminars, forums and workshops for business networking and new business development. These sessions will ensure that all attendees walking away with new ideas and solutions to implement into their current business. Alongside this, the new products exhibited in AAITF will account for 85% of new products within the entire industry, showcasing the latest models within the automotive aftermarket.
*New Trends *
AAITF 2019 will also display the new trends in this industry: the new products dominating the automotive aftermarket, the latest trends to look out for in the industry, the most effective shortcuts to expand the market share.
For more information, please visit the website: www.aaitf.org/en
Related Links :
http://www.aaitf.org/en Reported by PR Newswire Asia 5 minutes ago.
↧
Trump, Kim to Hold Second Nuclear Summit in February
President Trump and North Korean leader Kim Jong Un will meet for a second time in February, the White House announced Friday following a series of meetings between U.S. and North Korean officials in Washington.
Reported by Wall Street Journal 3 hours ago.
↧
↧
Apple to streamline team management in Apple Developer Program and App Store Connect
Apple in February will change the way it handles development teams for organizations, unifying individual memberships into a single set of roles across the Apple Developer website and App Store Connect.
Reported by AppleInsider 8 hours ago.
↧
Jaipur: Railway station gets airport-like makeover
As per the instructions by railway board, standards were set up regarding high-level illumination at 35 stations across the Indian Railways and these had to be completed by February end.
Reported by DNA 8 hours ago.
↧
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Danske Bank A/S – DNKEY
NEW YORK, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Danske Bank A/S (“Danske” or the “Company”) (OTC MKTS: DNKEY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.The investigation concerns whether Danske and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
*[Click here to join a class action]*
On September 5, 2017, Reuters reported that Danske had hired the former head of Denmark’s intelligence agency to help it in its effort to counter money-laundering claims. Then, on September 21, 2017, the Company issued a press release revealing that it had “expand[ed] its ongoing investigation into the situation at its Estonian branch.” Two months later, on December 21, 2017, Reuters reported that Danske “had been fined 12.5 million Danish crowns ($2 million)” by Denmark’s Financial Supervisory Authority (the “DFSA”) “for violating anti-money laundering rules in relation to the monitoring of transactions to and from correspondent banks,” and that Danske was “examining whether its Lithuanian and Latvian branches had been involved in money laundering, expanding an investigation beyond its Estonian operations.”
On May 3, 2018, Reuters reported the DFSA issued a report stating it had identified “serious weaknesses” in Danske’s governance and that the Company “was exposed ‘to significantly higher compliance and reputational risks than previously assessed.’”
On July 18, 2018, Danske stated that it wished to pay back approximately $230 million earned in connection with its alleged role in an international money laundering scheme involving illicit funds from Russia, Azerbaijan, and Moldova, calculated based on profit from Danske’s Estonian office. On this news, Danske’s American depositary receipt price fell $1.43, or 9.42%, to close at $13.81 on July 18, 2018.
On September 14, 2018, The Wall Street Journal disclosed that a whistleblower had approached the SEC at least two years earlier, and, as a result, U.S. law enforcement agencies had begun investigating the scandal.
On October 23, 2018, the full extent of the Company’s misconduct was releveled when The Wall Street Journal published an article disclosing that in 2013 the whistleblower had alerted Danske’s senior executives and that Danske sought to silence the whistleblower for years.
Upon the full revelation of the Company’s misconduct and the extent to which it relied upon the illegal profits, the price of the Company’s American Depositary Receipts (“ADRs”) had plummeted approximately 54%, from a high of $20.90 on February 16, 2018, to a low of $9.50 on October 23, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
*CONTACT:
*Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 9980 Reported by GlobeNewswire 8 hours ago.
*[Click here to join a class action]*
On September 5, 2017, Reuters reported that Danske had hired the former head of Denmark’s intelligence agency to help it in its effort to counter money-laundering claims. Then, on September 21, 2017, the Company issued a press release revealing that it had “expand[ed] its ongoing investigation into the situation at its Estonian branch.” Two months later, on December 21, 2017, Reuters reported that Danske “had been fined 12.5 million Danish crowns ($2 million)” by Denmark’s Financial Supervisory Authority (the “DFSA”) “for violating anti-money laundering rules in relation to the monitoring of transactions to and from correspondent banks,” and that Danske was “examining whether its Lithuanian and Latvian branches had been involved in money laundering, expanding an investigation beyond its Estonian operations.”
On May 3, 2018, Reuters reported the DFSA issued a report stating it had identified “serious weaknesses” in Danske’s governance and that the Company “was exposed ‘to significantly higher compliance and reputational risks than previously assessed.’”
On July 18, 2018, Danske stated that it wished to pay back approximately $230 million earned in connection with its alleged role in an international money laundering scheme involving illicit funds from Russia, Azerbaijan, and Moldova, calculated based on profit from Danske’s Estonian office. On this news, Danske’s American depositary receipt price fell $1.43, or 9.42%, to close at $13.81 on July 18, 2018.
On September 14, 2018, The Wall Street Journal disclosed that a whistleblower had approached the SEC at least two years earlier, and, as a result, U.S. law enforcement agencies had begun investigating the scandal.
On October 23, 2018, the full extent of the Company’s misconduct was releveled when The Wall Street Journal published an article disclosing that in 2013 the whistleblower had alerted Danske’s senior executives and that Danske sought to silence the whistleblower for years.
Upon the full revelation of the Company’s misconduct and the extent to which it relied upon the illegal profits, the price of the Company’s American Depositary Receipts (“ADRs”) had plummeted approximately 54%, from a high of $20.90 on February 16, 2018, to a low of $9.50 on October 23, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
*CONTACT:
*Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 9980 Reported by GlobeNewswire 8 hours ago.
↧
Donald Trump to meet Kim Jong-un again in late February: White House
During the meeting, the two leaders will hold talks over the steps taken by Pyongyang to dismantle its nuclear and missile programmes.
Reported by Zee News 7 hours ago.
↧
↧
Trump to meet N Korea's Kim again in February
US President Donald Trump will hold a second summit with North Korean leader Kim Jong-un in late February on Pyongyang dismantling its nuclear and missile programmes, the White House has announced. The two leaders had met on June 12 last year in Singapore for the first summit. The White House, however, did not identify a location for the second setting between the two leaders.
Reported by IndiaTimes 7 hours ago.
↧
Cubs' Bryant irked Harper, Machado still unsigned
The Cubs' Kris Bryant said "it's not good" that several free agents, including stars Bryce Harper and Manny Machado, are still looking for jobs as February nears.
Reported by ESPN 7 hours ago.
↧
ICC delays release of former Ivory Coast President until February
[The Netherlands], Jan 19 (ANI): The International Criminal Court (ICC) appeals' judges have delayed the release of former Ivory Coast President Laurent Gbagbo, despite being acquitted of all
Reported by Sify 7 hours ago.
↧
More Pages to Explore .....
